![]() ![]() ![]() The GeneTrails® Comprehensive Solid Tumor Panel has national coverage for qualifying Medicare and Medicare Advantage patients across all solid tumors. The DNA panel includes genes recently linked to immuno-therapy resistance (HLA, B2M, TAP, TAPBP, JAK1, IFNGR1, IFGR2). The partner-agnostic RNA gene fusion panel that is part of the CSTP encompasses all fusions for which FDA-approved therapies are available, as well as targets for ongoing clinical trials. In addition, it can be used to select therapies that have pan-cancer approval (pembrolizumab for MSI-high, larotrectinib and entrectinib for NTRK gene fusions). It covers genes that are informative for the use of FDA-approved therapies in non-small cell lung cancer (EGFR, BRAF, ALK, ROS1), colorectal cancer (KRAS, NRAS, BRAF), breast cancer (PIK3CA), and bladder cancer (FGFR2/3). CSTP is intended for the analysis of solid tumors from patients with clinically advanced disease (stage III or IV). ![]() The test can detect microsatellite instability and provides an estimate of tumor mutation burden (TMB). The GeneTrails ® Comprehensive Solid Tumor Panel (CSTP) is a next-generation sequencing (NGS) test comprised of two amplicon-based libraries (one DNA, one RNA/cDNA) used to screen for clinically informative gene alterations that are important in making therapeutic decisions, including SNVs, in/dels, copy number alterations and gene fusion events. GeneTrails® Solid Tumor Fusion Gene panel (RNA sequencing panel).Genes related to resistance to immune checkpoint inhibitor treatment (HLA genes, B2M, JAK1, JAK2, IFNGR1, IFGR2).Identification of microsatellite instability (MSI). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |